摘要
本文研究多肿瘤标志物(TM)联合定量检测对肝癌、胰腺癌和卵巢癌的临床应用价值。方法:采用蛋白芯片检测系统(C12),定量测定48例肝癌患者(A组)、29例胰腺癌患者(B组)、42例卵巢癌患者(C组)及74例良性相关疾病患者(D组)和66名正常人(对照组)血清中的12种肿瘤标志物,包括CA199、AFP、NSE、fPSA、CEA、PSA、CA242、CA125、CA153、铁蛋白、HGH和βHCG。结果表明:①A组AFP、CA125、铁蛋白、CEA、CA199和CA242的检测结果较D组和对照组有极其显著性差异(P<0.01)。βHCG有显著性差异(P<0.05)。本组联合检测的灵敏度为89.5%,特异性为87.32%,阳性预测值为70.49%,阴性预测值为96.12%,准确度为87.89%;②B组CA199、CA125、CA242、铁蛋白和CEA的检测结果较D组和对照组有显著性差异(P<0.01)。本组联合检测的灵敏度为82.76%,特异性为87.32%,阳性预测值为57.14%,阴性预测值为96.12%,准确度为86.55%;③C组CA125、铁蛋白、CEA、CA153、和CA242的检测结果较D组和对照组有极其显著性差异(P<0.01),CA199较对照组有显著性差异(P<0.05)。本组联合检测的灵敏度为80.95%,特异性为87.32%,阳性预测为65.38%,阴性预测值为93.94%,准确度为85.87%。总之多肿瘤标志物C12联合检测可提高相应肿瘤诊断的阳性率,不同类型的肿瘤选用相应多种肿瘤标志物联合检测,这样可为体检人群患癌症的早期筛查、术前和术后的临床跟踪等提供很好的依据。
To study the clinical application value of quantitative detection of 12 tumor markers in hepatocellular carcinoma, pancreatic cancer and ovarian cancer, the 12 tumor markers—CA125, ferritin, CEA, AFP, CA19-9,CA15-3, NSE, CA242, PSA, f-PSA, HGH and β-HCG in the serum of 48 patients with hepatocellular carcinoma, 29 patients with pancreatic cancer, 42 patients with ovarian cancer, 74 patients with benign disease and 66 healthy control persons were quantitatively detected by the protein biochip determination system of C-12. The results showed that ①The levels of AFP, CA125, ferritin, CEA, CA19-9, CA242 and β-HCG in patients with hepatocellular carcinoma were significantly higher than those in patients with benign disease and controls. The sensitivity, specificity, positive and negative predictive values, diagnostic efficiency by combinative detection were 89.58%, 87.32%,70.49%,96.12% and 87.89%, respectively. ②The levels of CA19-9, CA125, CA242, ferritin and CEA in patients with pancreatic cancer were significantly higher than those in patients with benign disease and controls(P<0.01). The sensitivity, specificity, positive and negative predictive values, diagnostic efficiency by combinative detection were 82.76%, 87.32%, 57.14%, 96.125% and 86.55%, respectively. ③The levels of CA125, CEA, CA15-3 and CA242 in patients with ovarian cancer were significantly higher than those in patients with benign disease and controls(P<0.01). The CA19-9 level was significantly higher than that in healthy persons(P<0.05). The sensitivity, specificity, positive and negative predictive values, diagnosing efficiency by combinative detection were 80.95%, 87.32%, 65.38%, 93.94% and 85.87%, respectively. In conclusion, combinative detection of various kinds of tumor markers should be adopted in diagnosis of different types of cancer. Detection of multi-tumor markers by using protein chip can be applied clinically for early screening diagnosis of tumor, as well as the patient’s prognosis and therapeutic effect.
出处
《标记免疫分析与临床》
CAS
2005年第2期100-103,共4页
Labeled Immunoassays and Clinical Medicine
关键词
肝癌
胰腺癌
卵巢癌
肿瘤标记物
联合检测
蛋白芯片
Hepatocellular carcinoma
Pancreatic cancer
Ovarian cancer
Tumor marker
Combinative detection
Protein chip
